Home » Endocrinology » TABLET Trial (2019): Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception

Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
TABLET trial levothyroxine

TABLET Trial Summary: Dhillon-Smith R et al. randomized 952 women with positive testing for thyroid peroxidase antibodies and normal thyroid function and a history of miscarriage or infertility to either levothyroxine 50 μg once daily (n=476) or placebo (n=476). The primary objective was to assess if levothyroxine treatment would increase live-birth rates among euthyroid women who had thyroid peroxidase antibodies and a history of miscarriage or infertility. No difference was noted among the primary outcome of live birth at >34 weeks gestation (RR 0.97; 95% CI, 0.83 to 1.14, P=0.74). There were no difference in adverse events. The authors of the TABLET trial concluded that the use of levothyroxine in euthyroid women with thyroid peroxidase antibodies did not result in a higher rate of live births than placebo.

Source: NEJM

TABLET Trial (2019): Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception